# North America Microarray Market

> North America Microarray Market Research Report Information, by type (Protein microarray, tissue microarray, cellular microarray), Tissue microarray by product (paraffin tissue sections (FFPE), frozen tissue sections), by application (immunohistochemistry, in-situ hybridization) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.87%
- **2024:** $ 1,575 Million
- **2025:** $ 1,659 Million
- **2035:** $ 2,656.5 Million
- **Key Players:** Thermo Fisher Scientific (US), Agilent Technologies (US), Illumina (US), Roche Diagnostics (US), PerkinElmer (US), Bio-Rad Laboratories (US), Arrayit Corporation (US), Luminex Corporation (US), Qiagen (DE), Merck KGaA (DE)

**Report ID:** MRFR/LS/1972-CR · **Pages:** 31 · **Author:** Rahul Gotadki · **Last Updated:** March 26, 2026

**URL:** https://www.marketresearchfuture.com/reports/north-america-microarray-market-2641

---

## Market Summary

## **North America Microarray Market Overview**

North America Microarray Market Size was valued at USD 0.29 Billion in 2023. The North America Microarray industry is projected to grow from USD 0.31 Billion in 2024 to USD 0.55 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.36% during the forecast period (2024 - 2032). North America the market for Microarray is increasing rapidly. A microarray is a multiplex lab-on-a-chip. It is a 2D array on a solid substrate, usually a glass slide or silicon thin-film cell, that assays large amounts of biological material using high-throughput screening miniaturized, multiplexed and parallel processing and detection methods.

Globally the microarray market is dominated by DNA microarrays. The protein microarray is currently the fastest growing market. The use of peptide and carbohydrate microarrays is expanding. Tissue and cell microarrays are in their infancy stage and are developing slowly because of many complications in the process development.

The AxiomTM PangenomiX Array*, the most ethnically diverse and largest array to date, was introduced by Thermo Fisher Scientific in January 2024. This array provides optimal genetic coverage for pharmacogenomic research and population-scale disease investigations.  The majority of the current large-scale genomic datasets, which are utilized for downstream meta-analysis to construct and comprehend disease risk prediction models, are derived from European and Caucasian cohorts. The urgent need for ethnically diverse data sets to generate genetic insights in other populations, such as African, Asian, and increasing mixed populations, is exacerbated by the increasingly diverse and blended global community.

Additionally, the healthcare sector is transitioning to a proactive care model, which underscores the significance of conducting research on the influence of genetics on drug response and disease risk.  At present, the PangenomiX Array is the sole research solution that integrates four assays into a single test: SNP genotyping, whole genome copy number variant detection, fixed copy number discovery, blood, and HLA typing. The high-throughput array is intended to facilitate the advancement of ancestry and wellness testing, population-scale disease research programs, drug efficacy testing, and drug development research, as well as disease risk and detection research. 

In September 2023, Thermo Fisher Scientific introduced a new chromosomal microarray that is intended to enhance the productivity, efficiency, and profitability of cytogenetic research labs. This microarray boasts an industry-leading two-day turnaround time. The Applied Biosystems™ CytoScan™ HD Accel array analyzes the entire human genome and offers enhanced coverage in over 5,000 critical genome regions, providing valuable insights on chromosomal variants for a diverse array of prenatal, postnatal, and oncology research applications.

Labs are under pressure to enhance efficacy in order to accommodate the increasing volumes, as there is a persistent shortage of trained laboratory professionals and a growing demand for laboratory services. The CytoScan HD Accel array has the potential to enhance the productivity of assays by up to 100% in laboratories that have an existing apparatus base. The new array also reduces the time required for sample handling and preparation, and it necessitates up to 50% less input sample—as little as 100 ng input DNA—than other commercially available chromosomal microarrays.

**Key Finding**

## **North America Microarray Market Segment Insights**

### **North America Microarray Type Insights**

North America Microarray market has been segmented on the basis of types which comprises of protein microarray, tissue microarray, and cellular microarray. 

### **North America Microarray Product Insights**

On the basis of product, North America Tissue microarray market is segmented into paraffin tissue sections (FFPE), frozen tissue sections, and others. 

### **North America Microarray Application**

On the basis of applications, 

[tissue microarray](../../../reports/tissue-microarray-market-1213)

 market is segmented into immunohistochemistry, in-situ hybridization, and others.

**Regional Analysis**

In North America, U.S. is the largest market for Tissue Microarray. Canada is the second-largest market and is expected to be fastest growing market for Tissue Microarray in North America.

**Key Players for North America Microarray Market**

Some of the key players in this North America Microarray Market are:

North America Microarray Market by Application

**Study objectives of Microarray Market:**

**Intended Audience**

The report for North America Microarray Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry.

The report also gives a broad study of the different markets segments and regions

### North America Microarray Market Industry Developments

- **Q1 2024: Thermo Fisher Launches Axiom PangenomiX Array, Its Largest and Most Ethnically Diverse Array to Date** Thermo Fisher Scientific announced the launch of the Axiom PangenomiX Array, designed to provide optimal genetic coverage for pharmacogenomic research and population-scale disease studies in the United States. The new product aims to improve accuracy in human genomic variation analysis.

## Market Drivers

### Growing Demand for Genomic Research

The North America Microarray Market is experiencing a surge in demand driven by the increasing focus on genomic research. As researchers and institutions strive to understand genetic variations and their implications on health, microarray technology becomes indispensable. The market is projected to grow at a compound annual growth rate (CAGR) of approximately 10% over the next five years, reflecting the escalating investment in genomic studies. This growth is further supported by the rising number of research initiatives funded by both public and private sectors, which aim to explore the genetic basis of diseases. Consequently, the North America Microarray Market is poised to benefit from this heightened interest in genomics, as it provides essential tools for high-throughput analysis and data generation.

### Supportive Government Policies and Funding

The North America Microarray Market is significantly influenced by supportive government policies and funding initiatives aimed at promoting research and development in genomics. Various federal and state programs provide grants and financial assistance to research institutions and companies engaged in microarray technology. For instance, the National Institutes of Health (NIH) has allocated substantial funding for genomic research projects, which directly benefits the microarray market. This financial backing encourages innovation and the development of new applications for microarrays in both research and clinical settings. As a result, the North America Microarray Market is likely to thrive, supported by a conducive regulatory environment that fosters growth and collaboration among stakeholders.

### Emergence of Advanced Microarray Technologies

The North America Microarray Market is witnessing the emergence of advanced microarray technologies that enhance the capabilities and applications of traditional microarrays. Innovations such as next-generation sequencing (NGS) and digital microarrays are revolutionizing the landscape, offering higher sensitivity and specificity in analyses. These advancements are expected to drive market growth, as researchers seek more efficient and accurate methods for gene expression profiling and genotyping. The introduction of user-friendly platforms and automation in microarray processing further contributes to the market's expansion. As these technologies gain traction, the North America Microarray Market is likely to see increased adoption across various sectors, including academia, [clinical diagnostics](https://www.marketresearchfuture.com/reports/clinical-diagnostic-market-41770), and pharmaceutical research.

### Integration of Microarrays in Clinical Diagnostics

The North America Microarray Market is witnessing a notable integration of microarray technology into clinical diagnostics. This trend is largely attributed to the increasing prevalence of chronic diseases and the need for accurate diagnostic tools. Microarrays facilitate the simultaneous analysis of multiple biomarkers, enabling healthcare providers to make informed decisions regarding patient care. According to recent data, the clinical diagnostics segment is expected to account for over 40% of the market share by 2026. This shift towards personalized medicine, where treatments are tailored based on individual genetic profiles, underscores the importance of microarrays in modern healthcare. As a result, the North America Microarray Market is likely to expand significantly as more healthcare facilities adopt these technologies.

### Rising Investment in Biotechnology and Pharmaceutical Sectors

The North America Microarray Market is benefiting from the rising investment in the biotechnology and pharmaceutical sectors. With a growing emphasis on drug discovery and development, microarrays play a crucial role in identifying potential drug targets and understanding drug interactions. The biotechnology sector alone is projected to reach a market value of over 700 billion USD by 2026, which will likely drive demand for microarray technologies. Furthermore, pharmaceutical companies are increasingly utilizing microarrays for biomarker discovery and validation, which enhances their research capabilities. This influx of investment not only bolsters the North America Microarray Market but also fosters innovation and the development of advanced microarray platforms.

## Future Outlook

The North America Microarray Market is projected to grow at a 4.87% CAGR from 2025 to 2035, driven by advancements in genomics, personalized medicine, and increasing research funding.

**New opportunities:**

- Development of high-throughput microarray platforms for large-scale genomic studies.
- Integration of AI-driven data analysis tools for enhanced interpretation of microarray results.
- Expansion of microarray applications in clinical diagnostics and personalized treatment plans.

By 2035, the North America Microarray Market is expected to be robust, driven by innovation and diverse applications.

## Segment Insights

### By Application: Genomics (Largest) vs. Diagnostics (Fastest-Growing)

In the North America Microarray Market, the application segments are diverse, with genomics currently being the largest segment, driven by the extensive use of microarrays in genetic analysis and research. The diagnostics segment, however, is rapidly gaining traction as healthcare advances toward personalized medicine, highlighting the increasing demand for precise diagnostic methods. As such, these segments play a crucial role in shaping the future of microarray applications in the region.
As healthcare continues to evolve, the growth trends within these segments indicate a more pronounced shift toward diagnostics, which has seen increased investments in technologies that enhance disease detection and monitoring. This, alongside developments in genomics aimed at better understanding the genetic basis of diseases, represents a dual momentum propelling the microarray market forward. The rising emphasis on research and development in genomics further supports this trajectory, establishing a robust foundation for sustained growth in both segments.

Genomics (Dominant) vs. Toxicogenomics (Emerging)

The genomics segment holds a dominant position in the North America Microarray Market, capitalizing on the vast applications ranging from genetic mapping to personalized medicine. This segment benefits from a mature infrastructure and substantial funding, facilitating advancements in technology and research. In contrast, toxicogenomics is emerging rapidly, focusing on understanding the toxic effects of chemicals on genes and biological systems. While still gaining popularity, toxicogenomics is recognized for its potential in risk assessment and regulatory compliance, particularly in pharmaceuticals and environmental studies. Thus, while genomics reflects a well-established area of expertise, toxicogenomics is expected to expand its footprint, driven by increasing regulatory pressures and public awareness surrounding toxic substances.

### By Technology: Array-based (Largest) vs. Sequencing-based (Fastest-Growing)

In the North America Microarray Market, the array-based technology enjoys the largest market share, significantly outperforming its counterparts in terms of adoption and utilization across various applications. This technology is foundational in areas such as gene expression profiling and genotyping, contributing to its substantial presence in the market. Conversely, the sequencing-based technology is rapidly gaining traction, being acknowledged as the fastest-growing segment due to its increasing applications in research and clinical diagnostics, particularly in personalized medicine.

The growth of these technologies is fueled by advancements in genomic research and a shift towards more precise diagnostic tools. Array-based technologies are favored for their high throughput and cost-effectiveness, while sequencing-based technologies are revolutionizing the market with innovations that enhance data accuracy and speed. Both segments are driven by rising investment in biotechnology and increasing demand for personalized healthcare solutions.

Technology: Array-based (Dominant) vs. PCR-based (Emerging)

Array-based technology stands as the dominant force in the North America Microarray Market, primarily due to its unparalleled efficiency and scalability in handling multiple assays simultaneously. It is extensively used in various fields such as genomics, transcriptomics, and epigenetics, establishing itself as a critical tool in research and clinical diagnostics. On the other hand, PCR-based technology is emerging as an important player in the market, gaining recognition for its sensitivity and specificity in identifying genetic variations. While PCR is fundamentally different from array-based methods, its ability to amplify specific DNA sequences is attracting significant attention, especially in applications related to disease detection and microbial testing. As both technologies evolve, their integration may pave the way for innovative solutions in the genomic landscape.

### By End Use: Research Laboratories (Largest) vs. Clinical Laboratories (Fastest-Growing)

In the North America Microarray Market, the segment distribution reveals that Research Laboratories hold the largest share, significantly contributing to the industry's overall growth. This segment benefits from extensive funding and initiatives aimed at enhancing research capabilities. Meanwhile, Clinical Laboratories are emerging as the fastest-growing segment, reflecting a shift towards personalized medicine and diagnostics that utilize microarray technologies.

Market Position: Research Laboratories (Dominant) vs. Clinical Laboratories (Emerging)

Research Laboratories play a critical role in the North America Microarray Market, as they are primarily responsible for groundbreaking research and innovation in genetic analysis and diagnostics. These laboratories often leverage advanced microarray technologies to conduct extensive experiments, leading to significant findings. In contrast, Clinical Laboratories are quickly gaining traction due to the increasing demand for effective diagnostic tools and personalized treatment approaches. This segment benefits from advancements in technology and regulatory support to implement microarray-based tests, thereby contributing to their rapid growth compared to Research Laboratories.

### By Product Type: DNA Microarrays (Largest) vs. RNA Microarrays (Fastest-Growing)

In the North America Microarray Market, [DNA Microarrays](https://www.marketresearchfuture.com/reports/dna-microarray-market-32328) hold the largest market share, primarily due to their extensive applications in genomic research and clinical diagnostics. RNA Microarrays, while smaller in scale, are rapidly gaining traction as they enable researchers to examine gene expression levels, which is vital in understanding disease mechanisms and therapeutic responses.
The growth of RNA Microarrays is driven by increasing investments in genomic research and the demand for personalized medicine. As healthcare evolves towards more individualized treatments, the utility of RNA Microarrays is becoming more pronounced. Additionally, advancements in technology and a decreasing cost of microarray production have contributed to increased adoption rates in research and clinical settings.

DNA Microarrays (Dominant) vs. Protein Microarrays (Emerging)

DNA Microarrays are currently dominant in the North America Microarray Market due to their broad applicability in genomics and their established role in diagnostics and research. They allow for high-throughput analysis and have been pivotal in genetic mapping and disease research. In contrast, Protein Microarrays are emerging as a significant player. They provide insights into proteomics and allow scientists to study protein interactions and functions on a large scale. Although they are less common than DNA Microarrays, their role in drug discovery and biomarker identification is becoming increasingly important, reflecting a growing trend towards proteomic analysis in research and therapeutic applications.

## Regional Market Share Analysis

### US : Leading Innovations and Investments

The US microarray market is valued at $1300.0 million, representing a significant share of approximately 82.9% of North America's total market. Key growth drivers include advancements in genomics and personalized medicine, alongside increasing demand for high-throughput screening technologies. Regulatory support from agencies like the FDA and initiatives promoting biotechnology research further bolster market growth. The robust infrastructure in states like California and Massachusetts enhances industrial development, facilitating innovation and production capabilities.

### Canada : Strategic Growth and Development

Canada's microarray market, valued at $275.0 million, accounts for about 17.1% of North America's market share. Growth is driven by rising investments in healthcare research and development, particularly in provinces like Ontario and British Columbia. Demand for microarray technologies is increasing in genomics and agricultural biotechnology sectors. Government initiatives, such as funding for health innovation, support the market's expansion, while a growing number of research institutions enhance the local ecosystem.

## Competitive Benchmarking

The Microarray Market in North America is characterized by a dynamic competitive landscape, driven by advancements in genomics and personalized medicine. Key players such as Thermo Fisher Scientific (US), Illumina (US), and Roche Diagnostics (US) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. Thermo Fisher Scientific (US) focuses on expanding its product portfolio through continuous innovation, while Illumina (US) emphasizes its leadership in next-generation sequencing technologies. Roche Diagnostics (US) is strategically positioned through its robust diagnostic solutions, which integrate microarray technology to improve patient outcomes. Collectively, these strategies foster a competitive environment that prioritizes technological advancement and market responsiveness.

In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The competitive structure of the Microarray Market appears moderately fragmented, with several key players exerting influence over market dynamics. This fragmentation allows for a diverse range of products and services, catering to various customer needs while fostering innovation through competition.

In December 2025, Illumina (US) announced a partnership with a leading biotechnology firm to develop a novel microarray platform aimed at accelerating genomic research. This collaboration is significant as it not only enhances Illumina's product offerings but also positions the company to capitalize on the growing demand for personalized medicine solutions. The strategic alliance is likely to bolster Illumina's competitive edge in the market, enabling it to deliver cutting-edge technologies to researchers and clinicians.

In November 2025, Roche Diagnostics (US) launched a new microarray-based diagnostic tool designed to detect multiple genetic disorders simultaneously. This innovation is pivotal as it addresses the increasing need for comprehensive genetic testing in clinical settings. By expanding its diagnostic capabilities, Roche Diagnostics (US) strengthens its market position and responds effectively to the evolving healthcare landscape, where rapid and accurate diagnostics are paramount.

In October 2025, Thermo Fisher Scientific (US) completed the acquisition of a smaller biotech firm specializing in microarray technology. This acquisition is indicative of Thermo Fisher's strategy to enhance its technological capabilities and expand its market share. By integrating the acquired firm's innovations, Thermo Fisher (US) is poised to offer more advanced solutions, thereby reinforcing its leadership in the Microarray Market.

As of January 2026, current competitive trends indicate a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) within microarray technologies. Strategic alliances are increasingly shaping the landscape, allowing companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve, shifting from price-based competition to a focus on technological innovation, reliability in supply chains, and the ability to deliver tailored solutions to meet the specific needs of customers.

## Recent News & Developments

- **Q1 2024: Thermo Fisher Launches Axiom PangenomiX Array, Its Largest and Most Ethnically Diverse Array to Date** Thermo Fisher Scientific announced the launch of the Axiom PangenomiX Array, designed to provide optimal genetic coverage for pharmacogenomic research and population-scale disease studies in the United States. The new product aims to improve accuracy in human genomic variation analysis.

## Report Scope

| MARKET SIZE 2024 | 1575.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 1659.0(USD Million) |
| MARKET SIZE 2035 | 2656.5(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.87% (2024 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Thermo Fisher Scientific (US), Agilent Technologies (US), Illumina (US), Roche Diagnostics (US), PerkinElmer (US), Bio-Rad Laboratories (US), Arrayit Corporation (US), Luminex Corporation (US), Qiagen (DE), Merck KGaA (DE) |
| Segments Covered | Application, Technology, End Use, Product Type |
| Key Market Opportunities | Advancements in personalized medicine drive demand for innovative applications in the North America Microarray Market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive growth in the North America Microarray Market. |
| Countries Covered | US, Canada |

## Frequently Asked Questions

**Q: What is the projected market valuation of the North America Microarray Market by 2035?**
A: The North America Microarray Market is projected to reach approximately 2656.5 USD Million by 2035.

**Q: What was the market valuation of the North America Microarray Market in 2024?**
A: In 2024, the North America Microarray Market was valued at 1575.0 USD Million.

**Q: What is the expected CAGR for the North America Microarray Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the North America Microarray Market during the forecast period 2025 - 2035 is 4.87%.

**Q: Which application segment is projected to have the highest valuation by 2035?**
A: The Diagnostics application segment is projected to reach approximately 900.0 USD Million by 2035.

**Q: What are the key technologies driving the North America Microarray Market?**
A: Key technologies include Array-based, Sequencing-based, PCR-based, and Hybridization-based methods.

**Q: Which company is a leading player in the North America Microarray Market?**
A: Thermo Fisher Scientific is among the leading players in the North America Microarray Market.

**Q: What is the projected valuation for the Sequencing-based technology segment by 2035?**
A: The Sequencing-based technology segment is projected to reach approximately 850.0 USD Million by 2035.

**Q: How does the market valuation of Pharmaceutical Companies compare to Clinical Laboratories in 2035?**
A: By 2035, the market valuation for Pharmaceutical Companies is projected to be around 800.0 USD Million, compared to 700.0 USD Million for Clinical Laboratories.

**Q: What is the expected market size for DNA Microarrays by 2035?**
A: The expected market size for DNA Microarrays is projected to reach approximately 1080.0 USD Million by 2035.

**Q: What is the anticipated growth trend for the North America Microarray Market?**
A: The North America Microarray Market appears to be on a growth trend, with a projected increase in valuation from 1575.0 USD Million in 2024 to 2656.5 USD Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/north-america-microarray-market-2641*